We are live on ! Find out more
EGRX

Eagle Pharmaceuticals, Inc.
EGRX

Delisted

EGRX was delisted on the 2nd of October, 2024.

Back to rankings

166 hedge funds and large institutions have $574M invested in Eagle Pharmaceuticals, Inc. in 2020 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 50 increasing their positions, 70 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

6% more capital invested

Capital invested by funds: $540M → $574M (+$33.3M)

3% less funds holding

Funds holding: 171 → 166 (-5)

23% less first-time investments, than exits

New positions opened: 17 | Existing positions closed: 22

29% less repeat investments, than reductions

Existing positions increased: 50 | Existing positions reduced: 70

Holders
166
Holders Change
-5
Holders Change %
-2.92%
% of All Funds
2.94%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
17
Increased
50
Reduced
70
Closed
22
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
PWAM
Park West Asset Management
California
+$7.25M
2
BIP
Brandes Investment Partners
California
+$5.12M
3
Two Sigma Advisers
Two Sigma Advisers
New York
+$3.13M
4
Two Sigma Investments
Two Sigma Investments
New York
+$2.5M
5
SG Americas Securities
SG Americas Securities
New York
+$1.74M

Top Sellers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
-$14.4M
2
Invesco
Invesco
Georgia
-$5.18M
3
Citadel Advisors
Citadel Advisors
Florida
-$4.16M
4
AL
AJO LP
Pennsylvania
-$4.15M
5
Renaissance Technologies
Renaissance Technologies
New York
-$2.75M
Name Holding Trade Value Shares
Change 		Change in
Stake
Skandinaviska Enskilda Banken (SEB)
76
Skandinaviska Enskilda Banken (SEB)
Sweden
$563K -$243K -5,200 -30%
Comerica Bank
77
Comerica Bank
Texas
$559K -$22.5K -481 -4%
New York State Common Retirement Fund
78
New York State Common Retirement Fund
New York
$540K – – –
Canada Life
79
Canada Life
Manitoba, Canada
$538K -$30.4K -650 -5%
SSA
80
Schonfeld Strategic Advisors
New York
$500K +$501K +10,712 New
CNAM
81
Campbell Newman Asset Management
Wisconsin
$494K +$37.1K +793 +8%
AG
82
Aperio Group
California
$493K +$132K +2,822 +36%
Royal Bank of Canada
83
Royal Bank of Canada
Ontario, Canada
$486K -$6.88K -147 -1%
Envestnet Asset Management
84
Envestnet Asset Management
Illinois
$450K -$35.6K -761 -7%
Thrivent Financial for Lutherans
85
Thrivent Financial for Lutherans
Minnesota
$447K -$20.7K -443 -4%
Deutsche Bank
86
Deutsche Bank
Germany
$442K +$62.3K +1,333 +16%
TPSF
87
Texas Permanent School Fund
Texas
$434K -$93.2K -1,992 -18%
SOADOR
88
State of Alaska Department of Revenue
Alaska
$420K -$108K -2,300 -20%
Fisher Asset Management
89
Fisher Asset Management
Washington
$419K -$1.45K -31 -0.3%
COPPSERS
90
Commonwealth of Pennsylvania Public School Employees Retirement System
Pennsylvania
$418K -$19.4K -414 -4%
CSS
91
Cubist Systematic Strategies
Connecticut
$401K +$128K +2,734 +47%
US Bancorp
92
US Bancorp
Minnesota
$399K -$7.44K -159 -2%
HSBC Holdings
93
HSBC Holdings
United Kingdom
$394K -$22.8K -487 -5%
Voloridge Investment Management
94
Voloridge Investment Management
Florida
$393K +$172K +3,679 +77%
Squarepoint
95
Squarepoint
New York
$390K -$232K -4,953 -37%
QI
96
QS Investors
New York
$386K – – –
Jane Street
97
Jane Street
New York
$368K -$56.8K -1,214 -13%
BIM
98
Bogle Investment Management
Massachusetts
$364K -$275K -5,881 -43%
Rafferty Asset Management
99
Rafferty Asset Management
New York
$350K -$553K -11,828 -61%
KAS
100
Kestra Advisory Services
Texas
$349K +$346K +7,400 +7,048%
2 3
4
5 6

EGRX Hedge Fund Activity: Q4 2020 in Review

166 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Eagle Pharmaceuticals, Inc. (EGRX) for Q4 2020, worth a combined $574M — up 6.2% from $540M a quarter earlier.

Sellers outnumbered buyers: 22 funds closed out of EGRX and 17 opened new positions — a net loss of 5 holders — while 70 trimmed existing stakes and 50 added.

The largest buyer was Park West Asset Management, adding an estimated $7.25M. The largest seller was Armistice Capital, cutting an estimated $14.4M.

  • 166 institutional investors held Eagle Pharmaceuticals, Inc. (EGRX) as of Q4 2020, down from 171 in Q3 2020.
  • Funds reported $574M of Eagle Pharmaceuticals, Inc. stock for Q4 2020, up 6.2% quarter-over-quarter.
  • 17 funds opened new Eagle Pharmaceuticals, Inc. positions in Q4 2020 and 22 closed out, a net change of -5 holders.
  • The largest Eagle Pharmaceuticals, Inc. buyer in Q4 2020 was Park West Asset Management, an estimated $7.25M added.
  • The largest Eagle Pharmaceuticals, Inc. seller in Q4 2020 was Armistice Capital, an estimated $14.4M sold.

Based on aggregated 13F filings for Q4 2020.